Our results further our previous observations that IL-6 augments Cisplatin-induced cancer cell stemness, implicating Cisplatin and IL-6R signaling as mediators of phenotypic changes in HNSCC tumors that result in enhanced stemness [16]. The gene discussed is IL6R; the disease is cancer.